AR056307A1 - Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas - Google Patents
Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticasInfo
- Publication number
- AR056307A1 AR056307A1 ARP060101362A ARP060101362A AR056307A1 AR 056307 A1 AR056307 A1 AR 056307A1 AR P060101362 A ARP060101362 A AR P060101362A AR P060101362 A ARP060101362 A AR P060101362A AR 056307 A1 AR056307 A1 AR 056307A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- alkoxyalkyl
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que las contienen. Reivindicacion 1: Un compuesto de formula (1), en la que: R1 representa un heteroarilo seleccionado del grupo que consiste en: imidazolilo, tiazolilo, piridilo, oxazolilo, pirazolilo, triazolilo, oxadiazolilo, quinolinilo, isoxazolilo, pirroloimidazoilo, y tiadiazol, en el que dicho heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados de -OH, -NR7R8, halogeno, alquilo C1-8, cicloalquilo C3-10, alcoxi C1-8, alcoxialquilo C1-12, hidroxialquilo C1-8, arilo C6-14 y bencilo; R2, R3 y A representan independientemente H o alquilo C1-8, en el que dicho alquilo está opcionalmente sustituido con uno o más -OH, alcoxi C1-8, -NR7R8 o halogeno; Q representa - (CH2)n-, en el que n = 1, 2, 3 o 4 o -(CH2)m-O-, en el que m = 2, 3 o 4; Z representa arilo C6-14, alquilo C1-8 o cicloalquilo C3-8; R4 y R5 representan cada uno independientemente H, halogeno, alquilo C1-8, arilo C6-14, ariloxi C6-14, alcoxi C1-8, heterocicloalquilo de 3-10 miembros o cicloalcoxi C3-8; en los que R4 y R5 están opcionalmente sustituidos con uno o más -OH, alcoxi C1-8, -NR7R8 o halogeno; Y representa -R6, -(CH2)o-R6-, -C(R6)3 o -CH(R6)2, en los que o = 1, 2 o 3; R6 representa H, arilo C6-14, alquilo C1-10, cicloalquilo C3-10, bicicloalquilo C5-18, tricicloalquilo C5-18, heterocicloalquilo de 3-10 miembros, heteroarilo de 5-10 miembros, -C(-O)NR7R8, o -C(-O)OR7, en los que dichos grupos R6 pueden estar opcionalmente sustituidos con uno o más grupos X; en los que X = -OH, alcoxi C1-8, -NR11R12, -SO2R10, -C(-O)R10, halogeno, ciano, alquilo C1-8, alcoxialquilo C1-10, heteroarilo de 5-10 miembros, arilo C6-14, ariloxi C6-14, bencilo, o hidroxialquilo C1-8; en los que R7 y R8 representan independientemente H, alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 5-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; en los que R7 y R8 pueden estar opcionalmente sustituidos con uno o más grupos X; o R7 y R8, junto con el nitrogeno al cual pueden estar unidos, pueden formar un grupo heterocicloalquilo de 3-10 miembros opcionalmente sustituido con uno o más grupos X; en los que R10 representa alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 3-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; en los que R11 y R12 representan independientemente H, alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo de 5-10 miembros, hidroxialquilo C1-8, heteroarilo de 5-10 miembros o alcoxialquilo C1-10; o sus sales, solvatos o profármacos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66947205P | 2005-04-08 | 2005-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056307A1 true AR056307A1 (es) | 2007-10-03 |
Family
ID=36649611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101362A AR056307A1 (es) | 2005-04-08 | 2006-04-06 | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060229455A1 (es) |
| EP (1) | EP1869019B1 (es) |
| JP (1) | JP4193949B2 (es) |
| KR (1) | KR100969402B1 (es) |
| CN (1) | CN101189228A (es) |
| AP (1) | AP2007004198A0 (es) |
| AR (1) | AR056307A1 (es) |
| AU (1) | AU2006231917B2 (es) |
| BR (1) | BRPI0608148A2 (es) |
| CA (1) | CA2603939C (es) |
| CR (1) | CR9493A (es) |
| DK (1) | DK1869019T3 (es) |
| DO (1) | DOP2006000078A (es) |
| EA (1) | EA014311B1 (es) |
| ES (1) | ES2520015T3 (es) |
| GE (1) | GEP20105053B (es) |
| GT (1) | GT200600136A (es) |
| HN (1) | HN2006013804A (es) |
| IL (1) | IL186409A (es) |
| MA (1) | MA29672B1 (es) |
| MX (1) | MX2007012463A (es) |
| NL (1) | NL1031539C2 (es) |
| NO (1) | NO339422B1 (es) |
| NZ (1) | NZ563238A (es) |
| PE (1) | PE20061400A1 (es) |
| TN (1) | TNSN07380A1 (es) |
| TW (1) | TW200719890A (es) |
| UA (1) | UA88518C2 (es) |
| UY (1) | UY29456A1 (es) |
| WO (1) | WO2006106425A1 (es) |
| ZA (1) | ZA200708481B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
| WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CN102143955B (zh) * | 2008-09-02 | 2013-08-14 | Omj制药公司 | 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物 |
| US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| WO2010107115A1 (ja) | 2009-03-19 | 2010-09-23 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AR077472A1 (es) * | 2009-07-15 | 2011-08-31 | Taisho Pharmaceutical Co Ltd | Inhibidores de transportador de glicina |
| CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| CA2779457C (en) | 2009-11-06 | 2017-10-17 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| JPWO2012036278A1 (ja) | 2010-09-17 | 2014-02-03 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
| JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| WO2012042539A2 (en) | 2010-09-28 | 2012-04-05 | Panacea Biotec Ltd | Novel bicyclic compounds |
| DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| MA39888A (fr) | 2014-04-24 | 2017-03-01 | Dart Neuroscience Cayman Ltd | Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 |
| TWI601712B (zh) | 2014-11-05 | 2017-10-11 | 達特神經科學（開曼）有限責任公司 | 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物 |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| CA3088356A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CA3133460A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| AU2020282757A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| AU2021205510A1 (en) | 2020-01-09 | 2022-07-21 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1058684A1 (en) | 1998-03-06 | 2000-12-13 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
| JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| EP1442018A1 (en) | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| MXPA06004279A (es) * | 2003-10-14 | 2006-06-28 | Pfizer Prod Inc | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina. |
| ES2777924T3 (es) | 2004-05-23 | 2020-08-06 | Hmi Medical Innovations Llc | Moduladores de teramuteína |
-
2006
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/en active Application Filing
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 CA CA2603939A patent/CA2603939C/en not_active Expired - Fee Related
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/en active Active
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es active Active
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko active IP Right Grant
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056307A1 (es) | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| DOP2007000014A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| ES2543607T3 (es) | Ciertas amidas sustituidas, método de obtención, y método de su uso | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR088534A1 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| AR059329A1 (es) | Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |